Developer of NGS-based genetic diagnostic devices. It is a molecular diagnostics company that offers whole-exome and whole-genome sequencing of normal and tumor tissue, respectively to detect inherited diseases, and assist physicians in the selection of therapy. The company has also developed HIVE, a clinical data management platform designed for clinical genomics. The company is also developing a genomics-based clinical decision support system. Founded in 2017, headquartered in Shenzhen, China. The company has raised $19.6M at the Series B stage backed by investors including Vinno Capital, DHVC, ASB Ventures, Insight Capital, Hengqin Financial Investment Group. Operating in Life Sciences > Genomics, Life Sciences > Clinical Genomics.
← All startups
Aegicare
Series BDeveloper of NGS-based genetic diagnostic devices. It is a molecular diagnostics company that offers whole-exome and whole-genome sequencing of normal and tumor tissue, respectively to detect inherited diseases, and assist physicians in the selection of therapy. The company has also developed HIVE, a clinical data management platform designed for clinical genomics. The company is also developing a genomics-based…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Portfolio of Sequencing-based Diagnostics
Institutional investors
Vinno CapitalDHVCASB VenturesInsight CapitalHengqin Financial Investment GroupHMC Ventures
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.